Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Molecular Partners Ag (MOLN) EBITDA Margin: 2020-2025

Historic EBITDA Margin for Molecular Partners Ag (MOLN) over the last 5 years, with Sep 2025 value amounting to -7,638.85%.

  • Molecular Partners Ag's EBITDA Margin fell 485809.00% to -7,638.85% in Q3 2025 from the same period last year, while for Sep 2025 it was -914.32%, marking a year-over-year decrease of 7723.00%. This contributed to the annual value of -1,231.73% for FY2024, which is 36347.00% down from last year.
  • Molecular Partners Ag's EBITDA Margin amounted to -7,638.85% in Q3 2025, which was down 1,019.03% from -682.63% recorded in Q2 2025.
  • Molecular Partners Ag's EBITDA Margin's 5-year high stood at 88.77% during Q1 2022, with a 5-year trough of -7,638.85% in Q3 2025.
  • For the 3-year period, Molecular Partners Ag's EBITDA Margin averaged around -1,914.43%, with its median value being -973.57% (2024).
  • Per our database at Business Quant, Molecular Partners Ag's EBITDA Margin tumbled by 664,575bps in 2021 and then spiked by 316,595bps in 2024.
  • Quarterly analysis of 5 years shows Molecular Partners Ag's EBITDA Margin stood at -352.11% in 2021, then slumped by 21,638bps to 62.48% in 2022, then crashed by 87,001bps to -807.54% in 2023, then tumbled by 27,927bps to -1,086.80% in 2024, then crashed by 485,809bps to -7,638.85% in 2025.
  • Its EBITDA Margin was -7,638.85% in Q3 2025, compared to -682.63% in Q2 2025 and -1,581.63% in Q1 2025.